Published in Viruses on November 24, 2015
Epithelial Junction Opener Improves Oncolytic Adenovirus Therapy in Mouse Tumor Models. Hum Gene Ther (2016) 0.78
Showing the Way: Oncolytic Adenoviruses as Chaperones of Immunostimulatory Adjuncts. Biomedicines (2016) 0.77
Oncolytic virotherapy for urological cancers. Nat Rev Urol (2016) 0.76
CXCL12 retargeting of an adenovirus vector to cancer cells using a bispecific adapter. Oncolytic Virother (2016) 0.75
Evaluation of CD46 re-targeted adenoviral vectors for clinical ovarian cancer intraperitoneal therapy. Cancer Gene Ther (2016) 0.75
A novel oncolytic adenovirus based on simian adenovirus serotype 24. Oncotarget (2017) 0.75
Whole cell vaccination using immunogenic cell death by an oncolytic adenovirus is effective against a colorectal cancer model. Mol Ther Oncolytics (2016) 0.75
Telomerase specific oncolytic adenovirus expressing TRAIL suppresses peritoneal dissemination of gastric cancer. Gene Ther (2017) 0.75
Pseudotyped αvβ6 integrin-targeted adenovirus vectors for ovarian cancer therapies. Oncotarget (2016) 0.75
Targeting Nucleotide Biosynthesis: A Strategy for Improving the Oncolytic Potential of DNA Viruses. Front Oncol (2017) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Integrated genomic analyses of ovarian carcinoma. Nature (2011) 47.72
Surfing the p53 network. Nature (2000) 35.36
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94
Cancer cell cycles. Science (1996) 21.29
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet (2008) 19.65
Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell (1993) 13.21
Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture. Proc Soc Exp Biol Med (1953) 9.43
PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol (2007) 6.24
Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med (1995) 5.85
Oncolytic virotherapy. Nat Biotechnol (2012) 5.79
The future of immune checkpoint therapy. Science (2015) 5.59
Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol (2010) 5.23
Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol (2008) 5.21
Adenovirus serotype 5 hexon mediates liver gene transfer. Cell (2008) 5.00
Control of early viral and bacterial distribution and disease by natural antibodies. Science (1999) 4.73
Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature (2006) 4.59
Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol (2007) 4.54
Tumor immunotherapy directed at PD-1. N Engl J Med (2012) 4.43
The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia (2006) 3.54
Adenovirus fiber disrupts CAR-mediated intercellular adhesion allowing virus escape. Cell (2002) 3.53
Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus. Clin Cancer Res (2013) 3.22
Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J Virol (2005) 3.19
CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res (2013) 3.02
Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proc Natl Acad Sci U S A (2008) 3.00
Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol (2005) 2.84
A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene (2000) 2.81
Crystal structure of the receptor-binding domain of adenovirus type 5 fiber protein at 1.7 A resolution. Structure (1994) 2.80
Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood (2006) 2.67
Neutralization of adenoviruses: kinetics, stoichiometry, and mechanisms. J Virol (1988) 2.61
Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin Diagn Lab Immunol (2004) 2.58
Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. Nat Med (2010) 2.58
Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer. Blood (2009) 2.55
Adenovirus type 5 and 7 capsid chimera: fiber replacement alters receptor tropism without affecting primary immune neutralization epitopes. J Virol (1996) 2.46
Virus binding to a plasma membrane receptor triggers interleukin-1 alpha-mediated proinflammatory macrophage response in vivo. Immunity (2009) 2.44
Going viral with cancer immunotherapy. Nat Rev Cancer (2014) 2.27
China approves world's first oncolytic virus therapy for cancer treatment. J Natl Cancer Inst (2006) 2.20
The structure of the human adenovirus 2 penton. Mol Cell (2005) 2.17
PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum Gene Ther (1999) 2.11
Phylogenetic analysis of the main neutralization and hemagglutination determinants of all human adenovirus prototypes as a basis for molecular classification and taxonomy. J Virol (2005) 2.09
Coagulation factor X activates innate immunity to human species C adenovirus. Science (2012) 2.09
CAR: a virus receptor within the tight junction. Adv Drug Deliv Rev (2005) 1.98
Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa. J Clin Microbiol (2006) 1.94
At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol (2013) 1.90
International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine (2011) 1.88
Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors. J Virol (2004) 1.86
Adenovirus serotype 5 fiber shaft influences in vivo gene transfer in mice. Hum Gene Ther (2003) 1.85
Virus treatment questioned after gene therapy death. Nature (1999) 1.81
Immune response to recombinant capsid proteins of adenovirus in humans: antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity. J Virol (1998) 1.75
A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther (2006) 1.74
Adenoviruses: update on structure and function. J Gen Virol (2009) 1.72
"Sero-switch" adenovirus-mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype. Hum Gene Ther (1996) 1.70
Identification of contact residues and definition of the CAR-binding site of adenovirus type 5 fiber protein. J Virol (2000) 1.65
Oncolytic viruses as therapeutic cancer vaccines. Mol Cancer (2013) 1.64
Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications. Virus Res (2007) 1.64
OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. Future Oncol (2010) 1.64
The GD1a glycan is a cellular receptor for adenoviruses causing epidemic keratoconjunctivitis. Nat Med (2010) 1.63
Clinical trials with oncolytic adenovirus in China. Curr Cancer Drug Targets (2007) 1.62
Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs. J Virol (1999) 1.61
Crystal structure of species D adenovirus fiber knobs and their sialic acid binding sites. J Virol (2004) 1.60
Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype. Hum Gene Ther (1997) 1.59
A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res (2000) 1.59
Adenovirus-based vaccines: comparison of vectors from three species of adenoviridae. J Virol (2010) 1.58
Primary culture of ovarian surface epithelial cells and ascites-derived ovarian cancer cells from patients. Nat Protoc (2006) 1.56
Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer Res (1999) 1.54
Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy. Gene Ther (2003) 1.54
Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol Immunother (2012) 1.54
Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1. Blood (2009) 1.51
Flexibility of the adenovirus fiber is required for efficient receptor interaction. J Virol (2003) 1.49
Intravascular adenoviral agents in cancer patients: lessons from clinical trials. Cancer Gene Ther (2002) 1.49
Adenovirus fiber. Curr Top Microbiol Immunol (1995) 1.49
In vivo hepatic adenoviral gene delivery occurs independently of the coxsackievirus-adenovirus receptor. Mol Ther (2002) 1.47
Potentiating cancer immunotherapy using an oncolytic virus. Mol Ther (2010) 1.46
Development of a generic adenovirus delivery system based on structure-guided design of bispecific trimeric DARPin adapters. Proc Natl Acad Sci U S A (2013) 1.46
Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement. Nat Med (2013) 1.45
Modification of adenovirus gene transfer vectors with synthetic polymers: a scientific review and technical guide. Mol Ther (2007) 1.43
Adenovirus infections in immunocompetent and immunocompromised patients. Clin Microbiol Rev (2014) 1.43
The adenovirus capsid protein hexon contains a highly conserved human CD4+ T-cell epitope. Hum Gene Ther (2002) 1.43
Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther (2001) 1.42
Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Ther (2001) 1.42
CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy. Mol Ther (2014) 1.40
Ovine adenovirus vectors overcome preexisting humoral immunity against human adenoviruses in vivo. J Virol (1999) 1.40
Postentry neutralization of adenovirus type 5 by an antihexon antibody. J Virol (2004) 1.40
A system for the propagation of adenoviral vectors with genetically modified receptor specificities. Nat Biotechnol (1999) 1.39
The cell adhesion molecule "CAR" and sialic acid on human erythrocytes influence adenovirus in vivo biodistribution. PLoS Pathog (2009) 1.37
Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector. Eur J Immunol (1995) 1.36
Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells. J Virol (2000) 1.33
Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumors. Clin Cancer Res (2010) 1.33
Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin Cancer Res (2004) 1.32
Complement activation by recombinant adenoviruses. Gene Ther (2001) 1.31
Deletion of penton RGD motifs affects the efficiency of both the internalization and the endosome escape of viral particles containing adenovirus serotype 5 or 35 fiber knobs. J Virol (2005) 1.31
Circumvention of vector-specific neutralizing antibody response by alternating use of human and non-human adenoviruses: implications in gene therapy. Virology (2000) 1.30
Directed evolution generates a novel oncolytic virus for the treatment of colon cancer. PLoS One (2008) 1.30
The therapeutic efficacy of adenoviral vectors for cancer gene therapy is limited by a low level of primary adenovirus receptors on tumour cells. Eur J Cancer (2002) 1.29
Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research. Front Oncol (2013) 1.29
Molecular evolution of human adenoviruses. Sci Rep (2013) 1.29
Targeting of adenovirus serotype 5 (Ad5) and 5/47 pseudotyped vectors in vivo: fundamental involvement of coagulation factors and redundancy of CAR binding by Ad5. J Virol (2007) 1.29
Identification of CD46 binding sites within the adenovirus serotype 35 fiber knob. J Virol (2007) 1.27